A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.